Model
Edge
Regeneron Pharmaceuticals, Inc.
REGN
Filing Type
10-Q
Filing Date
5/1/2024
Updated
5/2/24, 5:13 AM
Filing
10-Q
Earnings Release
Exhibits
10-Q
Q1
EX-10.1
AMENDMENT NO.2 TO MASTER AGREEMENT BETWEEN REGN AND ALNYLAM
EX-31.1
CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A)
EX-31.2
CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A)
EX-32
CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350